期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 21, 期 3, 页码 311-322出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2021.1825679
关键词
Avelumab; immune checkpoint inhibition; programmed death ligand-1; antibody-dependent cytotoxicity; chemotherapy; anti-angiogenesis; immunomodulation
This article provides an overview of current trials aiming to enhance ICI regimens using avelumab in combination with chemotherapeutic agents, antiangiogenetic drugs, and immunomodulators. Predictive factors for this type of immunochemotherapy are discussed.
Introduction Immune checkpoint inhibition (ICI) has proved successful for selected tumors and a subpopulation of patients. The human monoclonal IgG1 antibody (mAB) avelumab capable of mediating antibody-dependent cytotoxicity (ADCC) lysis is directed to programmed death ligand-1 (PD-L1) of tumor cells and is tested in trials aiming to improve ICI in combination with chemotherapeutic drugs. Areas covered This article presents an overview of the current trials to enhance ICI regimens using avelumab in combination with chemotherapeutics, antiangiogenetic drugs, and immunomodulators. Predictive factors for this kind of immunochemotherapy are discussed. Expert opinion Clinical data demonstrate that avelumab shows efficacy in cancer patients against Merkel cell carcinoma (MCC), renal cell carcinoma (RCC), and urothelial cancers as single agent. Furthermore, avelumab in combination with axitinib in RCC increases survival and exhibits activity in combination with docetaxel in urothelial carcinoma. However, several other immunochemotherapy trials for ovarian cancer, gastric cancer, and non-small lung cancer (NSCLC) showed no activity due to factors disfavoring administration of immunotherapy combos.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据